Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
This study is currently recruiting participants.
Study NCT00001962   Information provided by National Institutes of Health Clinical Center (CC)
First Received: January 18, 2000   Last Updated: November 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Aplastic Anemia
Pure Red Cell Aplasia
Diamond Blackfan Anemia
Additional conditions recognized in this trial
Anemia
Anemia, Aplastic
Anemia, Diamond-Blackfan
Red-Cell Aplasia, Pure
More general conditions related to this trial
Anemia, Hypoplastic, Congenital
Bone Marrow Diseases
Genetic Diseases, Inborn
Hematologic Diseases
Interventions listed in this trial
Daclizumab
Daclizumab (Zenapax)
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services